EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparison of Early Outcomes Following Transjugular Transcatheter Tricuspid Valve Replacement Between Large vs Small Annulus

Fei Chen, Xinyue Yang, Fan Qiao, Yuan Feng, Zhengang Zhao, Xin Wei, Xi Li, Tianyuan Xiong, Yi Zhang, Junbo Ge, Fanglin Lu, Mao Chen

JACC: Cardiovascular Interventions · 2026

DOI: 10.1016/j.jcin.2025.11.013 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Fei Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Cardiac Structure and Function, Institute of Cardiov…. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Tricuspid Valve, Heart Valve Prosthesis Implantation, Heart Valve Prosthesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter tricuspid valve replacement (TTVR) is a promising therapy for tricuspid regurgitation (TR), but comprehensive comparison of clinical outcomes stratified by annular size remains understudied. OBJECTIVES: The aim of this study was to evaluate and compare early outcomes in patients treated with transjugular TTVR stratified by annular size. METHODS: Patients with grade ≥3 TR undergoing LuX-Valve Plus TTVR were enrolled across 13 centers from May 2022 to March 2024. They were stratified into a large-annulus group (LAG) (perimeter-derived annular diameter ≥51 mm or maximal annular diameter ≥55 mm) and a small-annulus group (SAG). Early outcomes included device, procedural, or intraprocedural success; TR reduction; and 30-day primary endpoints or clinical success. RESULTS: Among 159 patients, baseline TR severity was greater in the LAG (n = 42) than the SAG (n = 117). Superior trial-defined device or procedural success (81.0% vs 97.4%; P = 0.001) and Tricuspid Valve Academic Research-defined intraprocedural success (78.6% vs 96.6%; P = 0.001) were observed in the SAG. At 30 days, primary endpoint rates were similar (trial defined, 16.7% vs 14.5% [P = 0.936]; TRISCEND II [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device] defined, 21.4% vs 22.2% [P = 1.000]), but Tricuspid Valve Academic Research Consortium clinical success favored the SAG (73.8% vs 94.9%; P = 0.001). Severe paravalvular regurgitation (7.1% vs 0.0%; P = 0.017) occurred only in the LAG, while new-onset third-degree atrioventricular block or pacemaker implantation (0.0% vs 9.4%) was exclusive to the SAG. Severe bleeding was comparable between the groups (14.3% vs 9.4%; P = 0.391). CONCLUSIONS: LuX-Valve Plus TTVR appears to be safe and effective in TR patients regardless of annular size, but TR reduction was more significant in the SAG, with specific differences in some major adverse events between groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tricuspid Valve InsufficiencyTricuspid ValveHeart Valve Prosthesis ImplantationHeart Valve ProsthesisCardiac CatheterizationHumansTreatment OutcomeFemaleMaleTime FactorsAgedProsthesis DesignRecovery of FunctionRisk FactorsAged, 80 and overRetrospective StudiesRisk AssessmentMiddle Aged

Stichwörter der Autor:innen

transcatheter tricuspid valve replacementtricuspid regurgitationtricuspid valve annulus

Autor:innen und Institutionen

  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, Ch…
  • Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China. Electronic address: jbge@zsh…
  • Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China. Electronic address: drlufanglin@yeah.net.

Zitieren

APA

Chen, F., Yang, X., Qiao, F., Feng, Y., Zhao, Z., Wei, X., Li, X., Xiong, T., Zhang, Y., Ge, J., Lu, F., & Chen, M. (2026). Comparison of Early Outcomes Following Transjugular Transcatheter Tricuspid Valve Replacement Between Large vs Small Annulus. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.11.013

Vancouver

Chen F, Yang X, Qiao F, Feng Y, Zhao Z, Wei X, et al. Comparison of Early Outcomes Following Transjugular Transcatheter Tricuspid Valve Replacement Between Large vs Small Annulus. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2025.11.013

BibTeX
@article{Chen2026,
  author = {Chen, Fei and Yang, Xinyue and Qiao, Fan and Feng, Yuan and Zhao, Zhengang and Wei, Xin and Li, Xi and Xiong, Tianyuan and Zhang, Yi and Ge, Junbo and Lu, Fanglin and Chen, Mao},
  title = {Comparison of Early Outcomes Following Transjugular Transcatheter Tricuspid Valve Replacement Between Large vs Small Annulus},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1016/j.jcin.2025.11.013}
}
Kostenlos starten →